Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CRMD Stock Summary
Top 10 Correlated ETFs
CRMD
In the News
CorMedix (CRMD) Q4 2023 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President, Chief Financial Officer Erin Mistry - Executive Vice President, Chief Commercial Officer Liz Hurlburt - Executive Vice President, Chief Clinical Strategy and Operations Officer Dan Ferry - LifeSci Advisors Conference Call Participants Jason Butler - Citizens JMP Anish Nikhanj - RBC Capital Markets Lew Sulewski - Truist Securities Serge Belanger - Needham & Co. Operator Good morning ladies and gentlemen, and welcome to the CorMedix Inc. fourth quarter and full year 2023 earnings call. At this time, all lines are in a listen-only mode.
CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2023, before the market opens on Tuesday, March 12, 2024, and will host a corporate update conference call at 8:30am Eastern Time.
U.S. FDA approves CorMedix's antimicrobial drug
The U.S. Food and Drug Administration (FDA) on Wednesday approved CorMedix's antimicrobial drug that aims to reduce catheter-related bloodstream infections (CRBSIs) in patients with kidney disease, the regulator said.
CorMedix Inc. (CRMD) Q3 2023 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Daniel Ferry - LifeSci Advisors Joseph Todisco - CEO Matt David - EVP and CFO Phoebe Mounts - EVP and General Counsel Conference Call Participants Jason Butler - JMP Securities Leszek Sulewski - Truist Securities Gregory Renza - RBC Capital Markets Operator Good afternoon, and welcome to CorMedix Third Quarter 2023 Earnings Conference Call. Today's call is being recorded.
CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023
BERKELEY HEIGHTS, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report its financial results for the third quarter ended September 30, 2023, after the market closes on Tuesday, November 14, 2023, and will host a corporate update conference call at 4:30pm Eastern Time.
CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be giving a company presentation at the Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 26 – 28, 2023.
Why Shares of CorMedix Are Slumping Thursday
CorMedix's lead therapy is DefenCath. The company is awaiting word from the FDA on the therapy's approval.
Why Is Cormedix (CRMD) Stock Down 23% Today?
Cormedix (NASDAQ: CRMD ) stock is falling hard on Thursday after the company priced a public offering of its shares. That public offering has the company selling 7.5 million shares of CRMD stock at a price of $4 per share.
Cormedix Inc. To Present At The Jefferies Healthcare Conference
BERKELEY HEIGHTS, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be presenting and participating in investor meetings at the Jefferies Healthcare Conference being held in New York on June 7 – 9, 2023.
CorMedix Inc. (CRMD) Q1 2023 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q1 2023 Earnings Call May 15, 2023 4:30 PM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Phoebe Mounts - Executive Vice President and General Counsel Erin Mistry - Executive Vice President and Chief Commercial Officer Conference Call Participants Serge Belanger - Needham & Company Operator Good afternoon, and welcome to the CorMedix First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.
CRMD Financial details
CRMD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.02 | 0.01 | 0.01 | 0.01 | 0 | |
Net income per share | -1.51 | -0.68 | -0.77 | -0.75 | -0.74 | |
Operating cash flow per share | -1.33 | -0.62 | -0.77 | -0.56 | -0.6 | |
Free cash flow per share | -1.33 | -0.62 | -0.77 | -0.6 | -0.61 | |
Cash per share | 0.99 | 1.18 | 1.63 | 1.74 | 1.47 | |
Book value per share | -10.05 | -8.09 | -7.61 | -6.52 | -6.84 | |
Tangible book value per share | 0.28 | 0.98 | 1.55 | 1.67 | 1.37 | |
Share holders equity per share | -10.05 | -8.09 | -7.61 | -6.52 | -6.84 | |
Interest debt per share | 0.34 | 0.03 | 0.04 | 0.02 | 0.02 | |
Market cap | 114.92M | 175.83M | 212.22M | 171.38M | 169.96M | |
Enterprise value | 103.42M | 159.3M | 171.15M | 118.75M | 127.39M | |
P/E ratio | -4.28 | -10.7 | -9.63 | -6.08 | -5.72 | |
Price to sales ratio | 267.38 | 620.71 | 887.07 | 897.58 | 2.6K | |
POCF ratio | -4.85 | -11.68 | -9.66 | -8.1 | -6.98 | |
PFCF ratio | -4.84 | -11.65 | -9.61 | -7.59 | -6.92 | |
P/B Ratio | -0.64 | -0.9 | -0.98 | -0.7 | -0.62 | |
PTB ratio | -0.64 | -0.9 | -0.98 | -0.7 | -0.62 | |
EV to sales | 240.62 | 562.39 | 715.42 | 621.95 | 1.95K | |
Enterprise value over EBITDA | -3.85 | -7.7 | -6.31 | -4.03 | -4.2 | |
EV to operating cash flow | -4.36 | -10.58 | -7.79 | -5.61 | -5.23 | |
EV to free cash flow | -4.35 | -10.56 | -7.75 | -5.26 | -5.18 | |
Earnings yield | -0.23 | -0.09 | -0.1 | -0.16 | -0.17 | |
Free cash flow yield | -0.21 | -0.09 | -0.1 | -0.13 | -0.14 | |
Debt to equity | -0.03 | 0 | 0 | 0 | 0 | |
Debt to assets | 0.33 | 0 | 0.02 | 0.01 | 0.01 | |
Net debt to EBITDA | 0.43 | 0.8 | 1.52 | 1.79 | 1.41 | |
Current ratio | 2.4 | 5.04 | 11.58 | 12.44 | 9.44 | |
Interest coverage | -14.34K | -26.68 | -819.26 | -1.85K | -1.15K | |
Income quality | 0.88 | 0.92 | 1 | 0.75 | 0.82 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 18.79 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 43.79 | 39.02 | 55.92 | 68.78 | 163.28 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.01 | 0.07 | 0.01 | |
Capex to revenue | -0.11 | -0.13 | -0.47 | -7.46 | -3.35 | |
Capex to depreciation | -0.66 | -0.5 | -0.88 | -23.03 | -2.59 | |
Stock based compensation to revenue | 2.58 | 8.61 | 10.45 | 26.41 | 62.22 | |
Graham number | 18.45 | 11.13 | 11.49 | 10.48 | 10.65 | |
ROIC | 0.16 | 0.08 | 0.1 | 0.12 | 0.11 | |
Return on tangible assets | -1.43 | -0.56 | -0.45 | -0.41 | -0.48 | |
Graham Net | 0.22 | 0.95 | 1.45 | 1.58 | 1.29 | |
Working capital | 10.9M | 23.52M | 44.02M | 61.12M | 53.24M | |
Tangible asset value | 4.93M | 23.65M | 44.22M | 62.8M | 55.06M | |
Net current asset value | 4.77M | 23.52M | 43.1M | 60.32M | 52.57M | |
Invested capital | -0.03 | 0 | 0 | 0 | 0 | |
Average receivables | 37.53K | 5.47K | 1.7K | 24.36K | 22.68K | |
Average payables | 2.2M | 1.81M | 1.08M | 1.67M | 2.21M | |
Average inventory | 511.35K | 383.49K | 241.01K | 73.29K | 1.5K | |
Days sales outstanding | 9.26 | 0.05 | 5.12 | 86.73 | 0 | |
Days payables outstanding | 2.38K | 1K | 2.01K | 5.41K | 215.26K | |
Days of inventory on hand | 394.19 | 331 | 255.81 | 7.37 | 0 | |
Receivables turnover | 39.42 | 8.09K | 71.26 | 4.21 | 0 | |
Payables turnover | 0.15 | 0.36 | 0.18 | 0.07 | 0 | |
Inventory turnover | 0.93 | 1.1 | 1.43 | 49.51 | 0 | |
ROE | 0.15 | 0.08 | 0.1 | 0.11 | 0.11 | |
Capex per share | 0 | 0 | 0 | -0.04 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.16 | -0.19 | 9.77 | -0.25 | -0.17 | |
Operating cash flow per share | -0.15 | -0.15 | -0.24 | -0.19 | -0.15 | |
Free cash flow per share | -0.15 | -0.15 | -0.24 | -0.19 | -0.15 | |
Cash per share | 1.43 | 1.41 | 1.27 | 1.16 | 1.53 | |
Book value per share | 1.37 | -6.58 | -6.48 | -6.55 | 1.47 | |
Tangible book value per share | 1.37 | 1.32 | 1.22 | 1.08 | 1.47 | |
Share holders equity per share | 1.37 | -6.58 | -6.48 | -6.55 | 1.47 | |
Interest debt per share | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
Market cap | 116.55M | 176.63M | 182.54M | 180.1M | 209.25M | |
Enterprise value | 74.13M | 134.06M | 157.81M | 160.95M | 156.64M | |
P/E ratio | -4.32 | -5.5 | 0.11 | -3.99 | -5.37 | |
Price to sales ratio | 17.1K | 5.95K | 0 | 0 | 0 | |
POCF ratio | -19.44 | -28.7 | -17.56 | -21.01 | -24.06 | |
PFCF ratio | -19.2 | -28.11 | -17.54 | -20.99 | -24.03 | |
P/B Ratio | 2.07 | -0.64 | -0.64 | -0.61 | 2.51 | |
PTB ratio | 2.07 | -0.64 | -0.64 | -0.61 | 2.51 | |
EV to sales | 10.87K | 4.51K | 0 | 0 | 0 | |
Enterprise value over EBITDA | -10.83 | -16.34 | -14.32 | -13.63 | -16.17 | |
EV to operating cash flow | -12.36 | -21.78 | -15.18 | -18.78 | -18.01 | |
EV to free cash flow | -12.21 | -21.33 | -15.16 | -18.76 | -17.99 | |
Earnings yield | -0.06 | -0.05 | 2.36 | -0.06 | -0.05 | |
Free cash flow yield | -0.05 | -0.04 | -0.06 | -0.05 | -0.04 | |
Debt to equity | 0.01 | 0 | 0 | 0 | 0.01 | |
Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 6.2 | 5.19 | 2.24 | 1.62 | 5.43 | |
Current ratio | 11.79 | 9.44 | 12.15 | 7.39 | 11.61 | |
Interest coverage | -793.29 | -955.93 | -1.26K | -2.02K | -798.24 | |
Income quality | 0.87 | 0.75 | 0.98 | 0.76 | 0.89 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 343.15 | 95.72 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.02 | 0 | 0 | 0 | |
Capex to revenue | -11.21 | -4.33 | 0 | 0 | 0 | |
Capex to depreciation | -3.59 | -5.72 | -0.88 | -0.36 | -0.58 | |
Stock based compensation to revenue | 144.28 | 29.43 | 0 | 0 | 0 | |
Graham number | 2.24 | 5.33 | 37.75 | 6.05 | 2.39 | |
ROIC | -0.12 | 0.03 | -1.58 | 0.04 | -0.12 | |
Return on tangible assets | -0.11 | -0.13 | 7.27 | -0.2 | -0.11 | |
Graham Net | 1.29 | 1.24 | 1.15 | 0.98 | 1.39 | |
Working capital | 54.6M | 53.24M | 52.11M | 47.24M | 81.39M | |
Tangible asset value | 56.31M | 55.06M | 53.93M | 49.05M | 83.2M | |
Net current asset value | 53.9M | 52.57M | 51.48M | 46.64M | 80.84M | |
Invested capital | 0.01 | 0 | 0 | 0 | 0.01 | |
Average receivables | 0.5 | 0.5 | 0 | 0 | 0 | |
Average payables | 2.13M | 1.98M | 1.82M | 2.17M | 2.64M | |
Average inventory | 994.5 | 134.5 | 0 | 0 | 0 | |
Days sales outstanding | 0.01 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 108.28K | 488.16K | 2.63K | 5.14K | 4.14K | |
Days of inventory on hand | 16.48 | 0 | 0 | 0 | 0 | |
Receivables turnover | 6.82K | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0.03 | 0.02 | 0.02 | |
Inventory turnover | 5.46 | 0 | 0 | 0 | 0 | |
ROE | -0.12 | 0.03 | -1.51 | 0.04 | -0.12 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CRMD Frequently Asked Questions
What is CorMedix Inc. stock symbol ?
CorMedix Inc. is a US stock , located in Berkeley heights of Nj and trading under the symbol CRMD
What is CorMedix Inc. stock quote today ?
CorMedix Inc. stock price is $4.16 today.
Is CorMedix Inc. stock public?
Yes, CorMedix Inc. is a publicly traded company.